Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Genmab A/S ADR (NQ: GMAB )

28.70 +0.37 (+1.31%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 361,029
Open 28.47
Bid (Size) 28.70 (3)
Ask (Size) 28.72 (2)
Prev. Close 28.33
Today's Range 28.45 - 28.81
52wk Range 26.32 - 42.72
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NASDAQ:GMAB is not too expensive for the growth it is showing.
Via Chartmill
ProfoundBio Discovers The Joys Of Having A Wealthy Owner
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a... 
Via Benzinga

Performance

YTD
-10.62%
-10.62%
1 Month
-3.17%
-3.17%
3 Month
-0.07%
-0.07%
6 Month
+0.17%
+0.17%
1 Year
-29.22%
-29.22%

More News

Read More
Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion
Via Talk Markets
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio
Via Investor's Business Daily
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
From Genmab A/S
Via Business Wire
Is NASDAQ:GMAB on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Analyst Ratings For Genmab
Via Benzinga
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
Why NASDAQ:GMAB Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
NASDAQ:GMAB is showing good growth, while it is not too expensive.
Via Chartmill
U.S. FDA Accepts for Priority Review the Supplemental Biologics License Application for Epcoritamab (EPKINLY®) for Difficult-to-Treat Relapsed or Refractory Follicular Lymphoma
From Genmab A/S
Via Business Wire
4 Analysts Assess Genmab: What You Need To Know
Via Benzinga
Earnings Outlook For Genmab
Via Benzinga
NASDAQ:GMAB, a strong growth stock, setting up for a breakout.
Via Chartmill
Cracking The Code: Understanding Analyst Reviews For Genmab
Via Benzinga
Investors seeking growth at a reasonable cost should explore NASDAQ:GMAB.
Via Chartmill
Investors should take note of NASDAQ:GMAB, a growth stock that remains attractively priced.
Via Chartmill
Tisotumab Vedotin Marketing Authorization Application Validated by European Medicines Agency for Treatment of Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
What's Going On With Danish Healthcare Firm Genmab Stock?
Via Benzinga
TIVDAK® (tisotumab vedotin-tftv) Supplemental Biologics License Application Accepted for Priority Review by U.S. Food and Drug Administration for Patients with Recurrent or Metastatic Cervical Cancer
From Genmab A/S
Via Business Wire
TIVDAK® Supplemental Biologics License Application Accepted for Priority Review by FDA for Patients with Recurrent or Metastatic Cervical Cancer
From Pfizer Inc.
Via Business Wire
NASDAQ:GMAB stands out as a growth opportunity that won't break the bank.
Via Chartmill
Oracle Reports Weak Sales, Joins Kinetik, Lucid Group And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
New Pivotal Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma (FL)
From Genmab A/S
Via Business Wire
In the world of growth stocks, NASDAQ:GMAB shines as a value proposition.
Via Chartmill
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.